501426-48-8

Upstream product

• 5446-18-4 2,4-dichlorophenyl hydrazine hydrochloride 
• 95-92-1 oxalic acid diethyl ester 
• 121-97-1 4-Methoxypropiophenone 
• 221385-22-4 ethyl 3-methyl-2,4-dioxo-4-phenylbutanoate lithium salt 

Downstream Products

• 895582-44-2 4-bromomethyl-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxylic acid ethyl ester 
• 501426-63-7 2-{4-[2-(2,4-dichloro-phenyl)-4-methyl-5-(piperidin-1-ylcarbamoyl)-2H-pyrazol-3-yl]-phenoxymethyl}-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 502486-92-2 NIDA 41057 
• 502486-89-7 NIDA 41020 
• 501426-61-5 1-(2,4-dichlorophenyl)-5-(4-hydroxyphenyl)-4-methyl-1H-pyrazole-3-carboxylic acid 
• 501426-60-4 1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-1H-pyrazole-3-carboxylic acid 

Relevant academic research and scientific papers

"One-poto" synthesis of 4-substituted 1,5-diaryl-1H-pyrazole-3- carboxylic acids via a MeONa/LiCl-mediated sterically hindered claisen condensation-Knorr reaction-hydrolysis sequence

A "one-poto" synthesis of 4-substituted 1,5-diaryl-1H-pyrazole-3- carboxylic acids was first reported in moderate to good yields. This concise procedure, featuring efficiency and green chemistry, was composed of MeONa/LiCl-mediated sterically hindered Claisen condensation, Knorr reaction and hydrolysis. Georg Thieme Verlag KG · Stuttgart · New York.

Imidazol-4-one and Imidazole-4-thione Compounds

Imidazol-4-one or imidazole-4-thione compounds of formula (I): wherein X, R1, R2, R3, R4, R5, and R6 are defined herein. Also disclosed is a method for treating a cannabinoid receptor-mediated disorder with these compounds.

THERAPEUTIC AGENTS

The present invention relates to a 1,5-diphenylpyrazole compound and its use in the treatment of obesity, psychiatric and neurological disorders, to methods for the its therapeutic use and to pharmaceutical compositions containing them.

THERAPEUTIC AGENTS

The present invention relates to a 1,5-diphenylpyrazole compound and its use in the treatment of obesity, psychiatric and neurological disorders, to methods for the its therapeutic use and to pharmaceutical compositions containing them.

Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: Development of central cannabinoid receptor ligands with lower lipophilicity

Exploration of the central CB1 cannabinoid receptors using positron emission tomography (PET) will allow for an understanding of the pharmacological and physiological role played by these receptors in the CNS. Current tracers are highly lipophi